Jean Holloway Sells 8,962 Shares of Artivion (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) SVP Jean Holloway sold 8,962 shares of Artivion stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $38.00, for a total transaction of $340,556.00. Following the sale, the senior vice president directly owned 185,095 shares of the company’s stock, valued at $7,033,610. The trade was a 4.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Artivion Stock Performance

Artivion stock traded down $0.21 during trading hours on Wednesday, hitting $38.41. The company had a trading volume of 460,494 shares, compared to its average volume of 509,518. Artivion, Inc. has a one year low of $21.97 and a one year high of $48.25. The firm has a market cap of $1.84 billion, a PE ratio of 61.30 and a beta of 1.60. The firm has a 50-day moving average of $41.42 and a 200 day moving average of $42.92. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.53 and a quick ratio of 2.62.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.03. The firm had revenue of $118.30 million for the quarter, compared to analysts’ expectations of $116.42 million. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The business’s revenue was up 19.2% compared to the same quarter last year. On average, sell-side analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current year.

Key Artivion News

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Analysts remain constructive — consensus rating is “Moderate Buy” with several buy/outperform notes and mid‑to‑high price targets that support investor demand. Artivion Receives Consensus Rating
• Positive Sentiment: Management will present at the Oppenheimer Healthcare MedTech & Services Conference (virtual fireside chat), giving the company an opportunity to update investors on growth drivers, product progress and commercial milestones. Conferences can re‑ignite buying interest if guidance or pipeline commentary is favorable. Artivion to Participate in Oppenheimer Conference
• Positive Sentiment: Large institutional investors have been adding exposure (Invesco and others increased stakes), which can provide a steady bid and signals confidence from professional investors. MarketBeat – Artivion Institutional Activity
• Neutral Sentiment: Recent quarterly results beat revenue and EPS estimates and showed strong year‑over‑year revenue growth; that supports the bull case but may already be reflected in the share price and analyst upgrades. MarketBeat – Artivion Earnings Summary
• Negative Sentiment: Multiple senior insiders sold stock over March 2–4 (including the CEO and several EVPs/SVPs). A concentrated block of insider sales often weighs on sentiment even when executives retain large holdings — markets can interpret it as opportunistic liquidity or as a signal of limited near‑term confidence. Insider Trades Alert

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in AORT. Kennedy Capital Management LLC grew its position in Artivion by 20.8% in the 2nd quarter. Kennedy Capital Management LLC now owns 367,762 shares of the company’s stock valued at $11,437,000 after purchasing an additional 63,205 shares during the period. Squarepoint Ops LLC bought a new position in shares of Artivion in the second quarter valued at $664,000. Sio Capital Management LLC grew its holdings in shares of Artivion by 31.0% during the second quarter. Sio Capital Management LLC now owns 158,736 shares of the company’s stock valued at $4,937,000 after buying an additional 37,558 shares during the last quarter. Atria Investments Inc bought a new stake in Artivion during the 2nd quarter worth approximately $244,000. Finally, Osterweis Capital Management Inc. purchased a new stake in Artivion in the 2nd quarter valued at $3,750,000. Institutional investors own 86.37% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Weiss Ratings upgraded Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, February 20th. Wall Street Zen lowered shares of Artivion from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Canaccord Genuity Group lowered their price objective on shares of Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research report on Friday, February 13th. Needham & Company LLC reissued a “buy” rating and set a $58.00 price target on shares of Artivion in a report on Monday, February 2nd. Finally, Citizens Jmp upped their price objective on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $48.97.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.